BioXcel Therapeutics Inc. (BTAI): 0 Analysts rated it as Sell BTAI


BioXcel Therapeutics Inc. (NASDAQ:BTAI) changes shares on Tuesday trading session, with a change of -0.76% or -$0.36 shares. The trading starts at $46.50 and closed at $47.24 throughout the day. The trading session low price was $45.59 and day high was $47.94 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.48 million while its average volume is 599.92K. In other hand, the BTAI market cap reached to $1.01B.

On July 9, 2020, BRIEF-Bioxcel Therapeutics Announces Compassionate Use Program At Massachusetts General Hospital For Bxcl501. According to the news reported on Reuters, * BIOXCEL THERAPEUTICS ANNOUNCES COMPASSIONATE USE PROGRAM AT MASSACHUSETTS GENERAL HOSPITAL FOR BXCL501 TO TREAT COVID-19 PATIENTS SUFFERING FROM DELIRIUM AND AGITATION Source text for Eikon: Further company coverage:

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -10.77% and down -2.39% for month. Its quarterly performance was 21.99% above, while its half year performance is up 170.20%. BTAI yearly performance stood at positive 412.91% and rise 220.88% for year-to-date. Current recommendation for BioXcel Therapeutics Inc. is 1.70.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. BTAI EPS (TTM) for 12-month is -2.36. EPS for this year is -53.00%, while for the next year its value is -3.12. Its EPS Q/Q reached -70.90%.

Let’s take a look on the analyst recommendations on BTAI for the current month and previous month. For the current month, 7 of 7 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 7 analysts participate in stock recommendation. Out of 7, 0 rated it sell, 7 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $70.00 – $200.00. Average target price for BTAI was reached at $116.86.

Artemis Investment Management LLP, Ikarian Capital, LLC and FMR, LLC are the top three holders in BioXcel Therapeutics Inc. (BTAI) stock. On Jun 29, 2020, Artemis Investment Management LLP has 0.7 million shares which valued 37.19 million. On Mar 30, 2020, Ikarian Capital, LLC owned 0.69 million shares which valued at 15.5 million. On Mar 30, 2020, FMR, LLC has a total of 0.61 million shares which valued at 13.53 million. In the end, FMR, LLC have 3.00% shares outstanding of BioXcel Therapeutics Inc. (BTAI) on Mar 30, 2020. The insider ownership moved to 0.50% and institutional holding shifted to 35.40%.

The company posted an EPS (TTM) of -2.36. According to the most recent quarter report on (Jun 2020), 9 analysts estimated an average EPS of -0.75, while -0.54 EPS posted a year ago period. Analyst Estimated EPS for BTAI published in the report was -$0.83 – -$0.58 during the same period. Comparing with last year, the average estimated EPS was -0.54 which is higher than -0.79 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for BTAI rise 69.92% for period of 200 days. SMA for 50 days was -9.74% which is showing red signal, while SMA-20 was -12.88%. The moving average value for BioXcel Therapeutics Inc. (BTAI) is 36.90 and 53.74 for 200 and 50 days respectively.